Mye-EUNITER
 
News
relative info
De titel van dit stukje
As part of this process, instead of fighting disease, immune cells.

Spinout secures £3.2m to develop novel cancer therapies

Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, launches today with a £3.2 million seed financing round led by transatlantic VC Epidarex Capital, with the Scottish Investment Bank, the investment arm of Scottish Enterprise, also investing.

Macomics, which was spun out by two Mye-EUNITER researchers from the University of Edinburgh, will use the proceeds of this fundraising round to develop novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body’s immune defence against tumours.

Macomics’ approach is based on leading academic research around macrophage biology, particularly in cancer, from the laboratory of Professor Jeffrey Pollard, Director of the MRC Centre for Reproductive Health at the University of Edinburgh, working with co-founder Dr Luca Cassetta.

Read more